Advertisement

Diabetology International

, Volume 8, Issue 1, pp 52–58 | Cite as

Vitamin D deficiency aggravates diabetes-induced muscle wasting in female mice

  • Yukinori Tamura
  • Haruko Fujito
  • Naoyuki Kawao
  • Hiroshi KajiEmail author
Original Article
  • 160 Downloads

Abstract

We recently reported that vitamin D deficiency aggravates diabetic bone loss in mice. Although vitamin D affects both muscle and bone, the role of the vitamin D state in diabetic muscle loss and muscle-bone relationships remains unclear. In the present study, we examined the effects of vitamin D deficiency on muscle mass, muscle differentiation and muscle-derived humoral factors linking muscle to bone in diabetic female mice. Diabetes was induced in mice by streptozotocin (STZ) injection after feeding with a normal or vitamin D-deficient diet for 6 weeks. Quantitative computed tomography analysis showed that tibial muscle mass was significantly decreased in diabetic mice compared with control mice 4 weeks after induction of diabetes. Vitamin D deficiency accelerated muscle loss in diabetic mice. Vitamin D deficiency augmented the decreases in Pax7 mRNA levels and the increases in muscle RING-Finger Protein-1 and atrogin-1 mRNA levels induced by diabetes in the gastrocnemius muscle of mice. Moreover, vitamin D deficiency decreased the mRNA levels of insulin-like growth factor-1, fibroblast growth factor-2 and osteoglycin in muscle of diabetic mice. In conclusion, we demonstrated that vitamin D deficiency aggravates muscle loss induced by diabetes in female mice. Vitamin D may exert significant effects on the maintenance of the musculoskeletal system partly through the muscle-bone relationships in diabetic state.

Keywords

Vitamin D Diabetes Muscle wasting Myoblast 

Notes

Acknowledgments

This study was supported by Grants-in-aid 26860152 and 15K08220 from the Ministry of Science, Education and Culture of Japan (to Y.T. and to H.K., respectively) and a grant from The Nakatomi Foundation.

Compliance with ethical standards

Conflict of interest

None.

Ethical standards

All institutional and national guidelines for the care and use of laboratory animals were followed.

References

  1. 1.
    Ahlqvist E, van Zuydam NR, Groop LC, McCarthy MI. The genetics of diabetic complications. Nat Rev Nephrol. 2015;11:277–87.CrossRefPubMedGoogle Scholar
  2. 2.
    Saller A, Maggi S, Romanato G, Tonin P, Crepaldi G. Diabetes and osteoporosis. Aging Clin Exp Res. 2008;20:280–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporos Int. 2007;18:427–44.CrossRefPubMedGoogle Scholar
  4. 4.
    Merlotti D, Gennari L, Dotta F, Lauro D, Nuti R. Mechanisms of impaired bone strength in type 1 and 2 diabetes. Nutr Metab Cardiovasc Dis. 2010;20:683–90.CrossRefPubMedGoogle Scholar
  5. 5.
    Krause MP, Riddell MC, Hawke TJ. Effects of type 1 diabetes mellitus on skeletal muscle: clinical observations and physiological mechanisms. Pediatr Diabetes. 2011;12:345–64.CrossRefPubMedGoogle Scholar
  6. 6.
    Park SW, Goodpaster BH, Lee JS, Kuller LH, Boudreau R, de Rekeneire N, et al. Excessive loss of skeletal muscle mass in older adults with type 2 diabetes. Diabetes Care. 2009;32:1993–7.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Park SW, Goodpaster BH, Strotmeyer ES, Kuller LH, Broudeau R, Kammerer C, et al. Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes Care. 2007;30:1507–12.CrossRefPubMedGoogle Scholar
  8. 8.
    Park SW, Goodpaster BH, Strotmeyer ES, de Rekeneire N, Harris TB, Schwartz AV, et al. Decreased muscle strength and quality in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes. 2006;55:1813–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Reske-Nielsen E, Harmsen A, Vorre P. Ultrastructure of muscle biopsies in recent, short-term and long-term juvenile diabetes. Acta Neurol Scand. 1977;55:345–62.CrossRefPubMedGoogle Scholar
  10. 10.
    Russell ST, Rajani S, Dhadda RS, Tisdale MJ. Mechanism of induction of muscle protein loss by hyperglycaemia. Exp Cell Res. 2009;315:16–25.CrossRefPubMedGoogle Scholar
  11. 11.
    Mathieu C, Gysemans C, Giulietti A, Bouillon R. Vitamin D and diabetes. Diabetologia. 2005;48:1247–57.CrossRefPubMedGoogle Scholar
  12. 12.
    Svoren BM, Volkening LK, Wood JR, Laffel LM. Significant vitamin D deficiency in youth with type 1 diabetes mellitus. J Pediatr. 2009;154:132–4.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Wolff AE, Jones AN, Hansen KE. Vitamin D and musculoskeletal health. Nat Clin Pract Rheumatol. 2008;4:580–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354:669–83.CrossRefPubMedGoogle Scholar
  15. 15.
    Lips P, van Schoor NM. The effect of vitamin D on bone and osteoporosis. Best Pract Res Clin Endocrinol Metab. 2011;25:585–91.CrossRefPubMedGoogle Scholar
  16. 16.
    Dawson-Hughes B. Serum 25-hydroxyvitamin D and muscle atrophy in the elderly. Proc Nutr Soc. 2012;71:46–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Beaudart C, Buckinx F, Rabenda V, Gillain S, Cavalier E, Slomian J, et al. The effects of vitamin D on skeletal muscle strength, muscle mass, and muscle power: a systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2014;99:4336–45.CrossRefPubMedGoogle Scholar
  18. 18.
    Girgis CM, Clifton-Bligh RJ, Hamrick MW, Holick MF, Gunton JE. The roles of vitamin D in skeletal muscle: form, function, and metabolism. Endocr Rev. 2013;34:33–83.CrossRefPubMedGoogle Scholar
  19. 19.
    Bhat M, Kalam R, Qadri SS, Madabushi S, Ismail A. Vitamin D deficiency-induced muscle wasting occurs through the ubiquitin proteasome pathway and is partially corrected by calcium in male rats. Endocrinology. 2013;154:4018–29.CrossRefPubMedGoogle Scholar
  20. 20.
    Mao L, Tamura Y, Kawao N, Okada K, Yano M, Okumoto K, et al. Influence of diabetic state and vitamin D deficiency on bone repair in female mice. Bone. 2014;61:102–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Tanaka K, Kanazawa I, Yamaguchi T, Yano S, Kaji H, Sugimoto T. Active vitamin D possesses beneficial effects on the interaction between muscle and bone. Biochem Biophys Res Commun. 2014;450:482–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Kawao N, Kaji H. Interactions between muscle tissues and bone metabolism. J Cell Biochem. 2015;116:687–95.CrossRefPubMedGoogle Scholar
  23. 23.
    Cohen S, Nathan JA, Goldberg AL. Muscle wasting in disease: molecular mechanisms and promising therapies. Nat Rev Drug Discov. 2015;14:58–74.CrossRefPubMedGoogle Scholar
  24. 24.
    Kuang S, Rudnicki MA. The emerging biology of satellite cells and their therapeutic potential. Trends Mol Med. 2008;14:82–91.CrossRefPubMedGoogle Scholar
  25. 25.
    D’Souza DM, Al-Sajee D, Hawke TJ. Diabetic myopathy: impact of diabetes mellitus on skeletal muscle progenitor cells. Front Physiol. 2013;4:379.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Garcia LA, King KK, Ferrini MG, Norris KC, Artaza JN. 1,25(OH)2vitamin D3 stimulates myogenic differentiation by inhibiting cell proliferation and modulating the expression of promyogenic growth factors and myostatin in C2C12 skeletal muscle cells. Endocrinology. 2011;152:2976–86.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Girgis CM, Clifton-Bligh RJ, Mokbel N, Cheng K, Gunton JE. Vitamin D signaling regulates proliferation, differentiation, and myotube size in C2C12 skeletal muscle cells. Endocrinology. 2014;155:347–57.CrossRefPubMedGoogle Scholar
  28. 28.
    Workeneh B, Bajaj M. The regulation of muscle protein turnover in diabetes. Int J Biochem Cell Biol. 2013;45:2239–44.CrossRefPubMedGoogle Scholar
  29. 29.
    Kandarian SC, Jackman RW. Intracellular signaling during skeletal muscle atrophy. Muscle Nerve. 2006;33:155–65.CrossRefPubMedGoogle Scholar
  30. 30.
    Lecker SH, Solomon V, Mitch WE, Goldberg AL. Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. J Nutr. 1999;129:227S–37S.PubMedGoogle Scholar
  31. 31.
    Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem. 1998;67:425–79.CrossRefPubMedGoogle Scholar
  32. 32.
    Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 2001;294:1704–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA. 2001;98:14440–5.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Lambertucci AC, Lambertucci RH, Hirabara SM, Curi R, Moriscot AS, Alba-Loureiro TC, et al. Glutamine supplementation stimulates protein-synthetic and inhibits protein-degradative signaling pathways in skeletal muscle of diabetic rats. PLoS ONE. 2012;7:e50390.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Chiu CY, Yang RS, Sheu ML, Chan DC, Yang TH, Tsai KS, et al. Advanced glycation end-products induce skeletal muscle atrophy and dysfunction in diabetic mice via a RAGE-mediated, AMPK-down-regulated, Akt pathway. J Pathol. 2016;238:470–82.CrossRefPubMedGoogle Scholar
  36. 36.
    Sanders KM, Scott D, Ebeling PR. Vitamin D deficiency and its role in muscle-bone interactions in the elderly. Curr Osteoporos Rep. 2014;12:74–81.CrossRefPubMedGoogle Scholar
  37. 37.
    Kaji H. Linkage between muscle and bone: common catabolic signals resulting in osteoporosis and sarcopenia. Curr Opin Clin Nutr Metab Care. 2013;16:272–7.CrossRefPubMedGoogle Scholar
  38. 38.
    Tanaka K, Matsumoto E, Higashimaki Y, Katagiri T, Sugimoto T, Seino S, et al. Role of osteoglycin in the linkage between muscle and bone. J Biol Chem. 2012;287:11616–28.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Tanaka K, Matsumoto E, Higashimaki Y, Sugimoto T, Seino S, Kaji H. FAM5C is a soluble osteoblast differentiation factor linking muscle to bone. Biochem Biophys Res Commun. 2012;418:134–9.CrossRefPubMedGoogle Scholar
  40. 40.
    Ito S, Harada A, Kasai T, Sakai Y, Takemura M, Matsui Y, et al. Use of alfacalcidol in osteoporotic patients with low muscle mass might increase muscle mass: an investigation using a patient database. Geriatr Gerontol Int. 2014;14(Suppl 1):122–8.CrossRefPubMedGoogle Scholar

Copyright information

© The Japan Diabetes Society 2016

Authors and Affiliations

  • Yukinori Tamura
    • 1
  • Haruko Fujito
    • 1
  • Naoyuki Kawao
    • 1
  • Hiroshi Kaji
    • 1
    Email author
  1. 1.Department of Physiology and Regenerative MedicineKindai University Faculty of MedicineOsakasayamaJapan

Personalised recommendations